호주 수면 무호흡증 기기 시장 – 2024-2031년

Report Overview
The Australia sleep apnea devices market reached US$ 2 billion in 2023 and is expected to reach US$ 3.46 billion by 2031, growing at a CAGR of 7.1% during the forecast period 2024-2031.
Sleep apnea is a disorder that causes a person to stop breathing while asleep. The brain tries to protect the person by waking you up enough to breathe, but this prevents restful, healthy sleep. Over time, this condition can cause serious complications. The resulting lack of oxygen activates a survival reflex that wakes up a person just enough to resume breathing. While that reflex keeps the person alive, it also interrupts the sleep cycle. 
It prevents restful sleep and can have other effects, including putting stress on the heart that can have potentially deadly consequences. Sleep apnea is uncommon but widespread. Experts estimate it affects about 5% to 10% of people worldwide. The symptoms of sleep apnea include feeling tired or even exhausted when waking up, daytime sleepiness, continuous snoring, disruptions in brain function, unusual breathing patterns, and insomnia. Medical devices such as CPAP, APAP, and BPAP are used to treat sleep apnea.
Market Dynamics: Drivers
Increasing prevalence of sleep apnea and sleeping disorders
The rising prevalence of sleep apnea and other sleeping disorders propels the market growth. For instance, according to an article published by the Parliament of Australia, Approximately one in five Australians are estimated to be affected by a major sleep disorder. These include Obstructive Sleep Apnoea (OSA), insomnia, Restless Legs Syndrome (RLS), circadian rhythm disorders, and central disorders of hypersomnolence.
The Sleep Health Foundation (SHF) National Survey estimated that 8.3 percent of the Australian adult population has been diagnosed with OSA. The prevalence of OSA increases with age, with the SHF National Survey highlighting that 5 percent of 18 to 24-year-olds have been diagnosed with OSA compared to 12 percent of people over 65 years of age. In addition, the SHF National Survey also outlined significant gender-based variation in the prevalence of OSA with 12.9 percent of men and 3.7 percent of women having been diagnosed with OSA.
Restraints
Factors such as lack of awareness among people are expected to hamper the market. The lack and insufficient awareness of sleep apnea and its further consequences act as restraints for the sleep apnea devices market. Many individuals are not aware of the symptoms of sleep apnea which keeps them undiagnosed. 
Market Segment Analysis
The Australia sleep apnea devices market is segmented based on device type, disease type, and, end-user
The segment therapeutic devices accounted for approximately 43.5% of the Australia sleep apnea devices market share.
The therapeutic devices segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.
A positive airway pressure(PAP) device is the most widely used therapeutic device for the treatment of sleep apnea. In the PAP devices, there are three types of devices namely, continuous PAP(CPAP), auto-adjusting PAP(APAP), and bilevel PAP(BPAP). Among these three CPAP is most widely used. A CPAP machine takes in room air, then filters and pressurizes it before delivering it through a tube and into the mask. The continuous flow of air gently keeps the tongue, uvula, and soft palate from shifting too far into the airway. This stabilizes breathing and improves the overall sleep quality.
For instance, in February 2024, ResMed announced the launch of a new bi-level respiratory support device that will give doctors another option for treating their patients with sleep apnea beyond the segment-dominating CPAP machines. The AirCurve 11 device is compatible with all of ResMed’s masks. Bi-level devices like the AirCurve 11 provide two forms of positive airway pressure therapy with different pressure levels depending on whether a user is inhaling or exhaling compared to the single-level, continuous positive airway pressure of a CPAP machine.
Market Segmentation
By Device Type
Therapeutic Devices
CPAP
APAP
BPAP
Others 
By Disease Type
Obstructive Sleep Apnea Syndrome
Central Sleep Apnea Syndrome
Complex Sleep Apnea Syndrome
By End-User
Hospitals and Clinics
Sleep Laboratories
Homecare
Others
Market Competitive Landscape
The major players in the Australia sleep apnea devices market include Respirico Scooter World, ResMed, Drive DeVilbiss International, Koninklijke Philips N.V, Fisher & Paykel Healthcare Limited, SomnoMed, Seatec, Compumedics Limited, General Electric Company, Cadwell Industries Inc. among others. 
Key Developments
In February 2024, The US Food and Drug Administration granted 510(k) clearance to Masimo’s MightySat Medical fingertip pulse oximeter for over-the-counter use. The clearance makes it the first FDA-cleared medical fingertip pulse oximeter available over-the-counter, directly to consumers without a prescription, according to a release from Masimo. The device is powered by Masimo SET pulse oximetry, the same technology relied on by hospitals and clinics to monitor patients.
In December 2023, The US Food and Drug Administration (FDA) granted 510(k) clearance to Australia-based Compumedics’ Somfit device, an adhesive device worn on a patient’s forehead to collect physiological data, used primarily to assist in diagnosing sleep disorders.
Why Purchase the Report?
To visualize the Australia sleep apnea devices market segmentation based on device type, disease type, and end-user well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of Australia sleep apnea devices market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The Australia sleep apnea devices market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies